Choose a specialty to learn about CIMplicity® services specific to your patients

The CIMplicity program is provided as a service of UCB, Inc. and is intended to support the appropriate use of CIMZIA. The CIMplicity program may be amended or canceled at any time without notice. Eligibility and restrictions apply.

CIMplicity support for rheumatology patients

Enroll your patients in CIMplicity today

ONLINE
Follow the simple steps at CIMplicityCares.com.

FAX
Fax completed Patient Enrollment Forms to 1-866-949-2469.

Forms and resources

CIMplicity Patient Enrollment Form

Simple 1-page form to enroll your patients in CIMplicity.

DOWNLOAD

Prescribing Information Guide

See how to navigate the CIMZIA Prescribing Information.

DOWNLOAD

Patient Assistance Program Enrollment Form

The PAP can help uninsured patients access treatment. Your patients can learn more through UCBCares®.

LEARN MORE

Letter of Medical Necessity Guide
Learn the ins and outs of the LMN process.
DOWNLOAD

Prior Authorization Guide

Learn more information about filling out PA forms.

DOWNLOAD

Current CIMZIA Access Information

Learn about coverage for your patients.

DOWNLOAD for Prefilled Syringe

DOWNLOAD for In-office Injection

Real-time, comprehensive insurance support

"Experienced case managers are available to answer questions about coverage, PAs, and appeal management."
-Liz Mitchell

Image
CIMplicity Nurse Support video

Have questions or need help getting started?

Contact CIMplicity at
1-866-4-CIMZIA
(1-866-424-6942)
or request a UCB representative.

CIMplicity Covered®—on treatment, as soon as possible for your nr‑axSpA patients*

CIMplicity Covered lets your eligible, commercially insured patients start CIMZIA at no cost for up to two years or until the patient's coverage is approved, whichever comes first.

Just submit these forms

1. CIMplicity Patient Enrollment Form

2. PA

*CIMplicity Covered Eligibility: For eligible, commercially insured patients only. View complete eligibility requirements and terms at cimzia.com/cimplicity-program.

ONCE YOUR PATIENT'S INSURANCE IS APPROVED

Help your eligible, commercially insured patients save on their prescription. All you need to do is enroll them in CIMplicity.

Image
savings card
  • Eligible patients
  • pay as little as

$

0

co-pay

for their CIMZIA prescription with the CIMplicity Savings Program.

Savings Program Eligibility: Available to individuals with commercial prescription insurance for CIMZIA. Not valid for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal- or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law. Other restrictions apply. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, TRICARE, VA, and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice. View full eligibility.

Your patients can speak directly with a dedicated CIMplicity Nurse Navigator

You can offer your patients personalized nurse support just by enrolling them in CIMplicity. 

"Dedicated nurses provide patients with services that reinforce the education and treatment plan provided by their doctor."
-Liz Mitchell

The CIMplicity Nurse Program does not provide medical advice and does not replace the care of the healthcare provider. Nurse Navigators will refer your patient to their healthcare provider for any treatment-related questions.

Image
CIMplicity Nurse Support video

Show patients how to
self-inject

Give a comprehensive overview of how to self-inject with this step-by-step training video.

Looking for more support?

Our representatives are ready to answer questions you have about CIMplicity and CIMZIA.

For support with access and reimbursement, call CIMplicity at 1-866-4-CIMZIA (1-866-424-6942).

Eligibility and restrictions

CIMplicity Covered Eligibility

Eligible patients with a valid prescription for CIMZIA can receive treatment with the CIMZIA Prefilled Syringe at no cost for up to two years or until the patient’s coverage is approved, whichever comes first. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program or where otherwise prohibited by law. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. For initial enrollment into the program, the patient must be experiencing a delay in, or have been denied, coverage for CIMZIA by their commercial insurance plan. To maintain eligibility in the program, the following are required: (1) a prior authorization request has been submitted and/or coverage remains unavailable for the patient; and (2) if the prior authorization is denied by the payer, the prescriber must submit an appeal within the first sixty (60) days of the prior authorization denial and a prior authorization must be submitted every six (6) months thereafter or documentation as may otherwise be required by the payer. UCB reserves the right to rescind, revoke, or amend this Program without notice.

CIMplicity Savings Card Eligibility

Available to individuals with commercial prescription insurance coverage for a valid prescription of an FDA-approved indication for CIMZIA. Not valid for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal- or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (ie, Medicare, Medicaid, Medigap, TRICARE, VA, and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice.

The CIMplicity program is provided as a service of UCB and is intended to support the appropriate use of CIMZIA. The CIMplicity program may be amended or canceled at any time without notice. Eligibility and restrictions apply.

LMN: letter of medical necessity; PA: prior authorization; PAP: Patient Assistance Program.

CIMplicity support for gastroenterology patients

Enroll your patients in CIMplicity today

ONLINE
Follow the simple steps at CIMplicityCares.com.

FAX
Fax completed Patient Enrollment Forms to 1-866-949-2469.

Forms and resources

CIMplicity Patient Enrollment Form

Simple 1-page form to enroll your patients in CIMplicity.

DOWNLOAD

Prescribing Information Guide

See how to navigate the CIMZIA Prescribing Information.

DOWNLOAD

Patient Assistance Program Enrollment Form

The PAP can help uninsured patients access treatment. Your patients can learn more through UCBCares®.

LEARN MORE

Letter of Medical Necessity Guide
Learn the ins and outs of the LMN process.
DOWNLOAD

Prior Authorization Guide

Learn more information about filling out PA forms.

DOWNLOAD

Current CIMZIA Access Information

Learn about coverage for your patients.

DOWNLOAD for Prefilled Syringe

DOWNLOAD for In-office Injection

Real-time, comprehensive insurance support

"Experienced case managers are available to answer questions about coverage, PAs, and appeal management."
-Liz Mitchell

Image
CIMplicity Nurse Support video

Have questions or need help getting started?

Contact CIMplicity at
1-866-4-CIMZIA
(1-866-424-6942)
or request a UCB representative.

Help your eligible, commercially insured patients save on their prescription. All you need to do is enroll them in CIMplicity.

Image
savings card
  • Eligible patients
  • pay as little as

$

0

co-pay

for their CIMZIA prescription with the CIMplicity Savings Program.

Savings Program Eligibility: Available to individuals with commercial prescription insurance for CIMZIA. Not valid for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal- or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law. Other restrictions apply. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, TRICARE, VA, and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice. View full eligibility.

Your patients can speak directly with a dedicated CIMplicity Nurse Navigator

You can offer your patients personalized nurse support just by enrolling them in CIMplicity. 

"Dedicated nurses provide patients with services that reinforce the education and treatment plan provided by their doctor."
-Liz Mitchell

The CIMplicity Nurse Program does not provide medical advice and does not replace the care of the healthcare provider. Nurse Navigators will refer your patient to their healthcare provider for any treatment-related questions.

Image
CIMplicity Nurse Support video

Show patients how to
self-inject

Give a comprehensive overview of how to self-inject with this step-by-step training video.

Looking for more support?

Our representatives are ready to answer questions you have about CIMplicity and CIMZIA.

For support with access and reimbursement, call CIMplicity at 1-866-4-CIMZIA (1-866-424-6942).

Eligibility and restrictions

CIMplicity Covered Eligibility

Eligible patients with a valid prescription for CIMZIA can receive treatment with the CIMZIA Prefilled Syringe at no cost for up to two years or until the patient’s coverage is approved, whichever comes first. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program or where otherwise prohibited by law. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. For initial enrollment into the program, the patient must be experiencing a delay in, or have been denied, coverage for CIMZIA by their commercial insurance plan. To maintain eligibility in the program, the following are required: (1) a prior authorization request has been submitted and/or coverage remains unavailable for the patient; and (2) if the prior authorization is denied by the payer, the prescriber must submit an appeal within the first sixty (60) days of the prior authorization denial and a prior authorization must be submitted every six (6) months thereafter or documentation as may otherwise be required by the payer. UCB reserves the right to rescind, revoke, or amend this Program without notice.

CIMplicity Savings Card Eligibility

Available to individuals with commercial prescription insurance coverage for a valid prescription of an FDA-approved indication for CIMZIA. Not valid for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal- or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (ie, Medicare, Medicaid, Medigap, TRICARE, VA, and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice.

The CIMplicity program is provided as a service of UCB and is intended to support the appropriate use of CIMZIA. The CIMplicity program may be amended or canceled at any time without notice. Eligibility and restrictions apply.

LMN: letter of medical necessity; PA: prior authorization; PAP: Patient Assistance Program.

CIMplicity support for dermatology patients

Enroll your patients in CIMplicity today

ONLINE
Follow the simple steps at CIMplicityCares.com.

FAX
Fax completed Patient Enrollment Forms to 1-866-949-2469.

Forms and resources

CIMplicity Patient Enrollment Form

Simple 1-page form to enroll your patients in CIMplicity.

DOWNLOAD

Prescribing Information Guide

See how to navigate the CIMZIA Prescribing Information.

DOWNLOAD

Patient Assistance Program Enrollment Form

The PAP can help uninsured patients access treatment. Your patients can learn more through UCBCares®.

LEARN MORE

Letter of Medical Necessity Guide
Learn the ins and outs of the LMN process.
DOWNLOAD

Prior Authorization Guide

Learn more information about filling out PA forms.

DOWNLOAD

Current CIMZIA Access Information

Learn about coverage for your patients.

DOWNLOAD for Prefilled Syringe

DOWNLOAD for In-office Injection

CIMplicity Covered®—on treatment, as soon as possible*

CIMplicity Covered lets your eligible, commercially insured patients start CIMZIA at no cost for up to two years or until the patient's coverage is approved, whichever comes first.

Just submit these forms

1. CIMplicity Patient Enrollment Form

2. PA

*CIMplicity Covered Eligibility: For eligible, commercially insured patients only. View complete eligibility requirements and terms at cimzia.com/cimplicity-program.

ONCE YOUR PATIENT'S INSURANCE IS APPROVED

Help your eligible, commercially insured patients save on their prescription. All you need to do is enroll them in CIMplicity.

Image
savings card
  • Eligible patients
  • pay as little as

$

0

co-pay

for their CIMZIA prescription with the CIMplicity Savings Program.

Savings Program Eligibility: Available to individuals with commercial prescription insurance for CIMZIA. Not valid for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal- or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law. Other restrictions apply. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, TRICARE, VA, and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice. View full eligibility.

Your patients can speak directly with a dedicated CIMplicity Nurse Navigator

You can offer your patients personalized nurse support just by enrolling them in CIMplicity. 

"Dedicated nurses provide patients with services that reinforce the education and treatment plan provided by their doctor."
-Liz Mitchell

The CIMplicity Nurse Program does not provide medical advice and does not replace the care of the healthcare provider. Nurse Navigators will refer your patient to their healthcare provider for any treatment-related questions.

Image
CIMplicity Nurse Support video

Show patients how to
self-inject

Give a comprehensive overview of how to self-inject with this step-by-step training video.

Looking for more support?

Our representatives are ready to answer questions you have about CIMplicity and CIMZIA.

For support with access and reimbursement, call CIMplicity at 1-866-4-CIMZIA (1-866-424-6942).

Eligibility and restrictions

CIMplicity Covered Eligibility

Eligible patients with a valid prescription for CIMZIA can receive treatment with the CIMZIA Prefilled Syringe at no cost for up to two years or until the patient’s coverage is approved, whichever comes first. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program or where otherwise prohibited by law. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. For initial enrollment into the program, the patient must be experiencing a delay in, or have been denied, coverage for CIMZIA by their commercial insurance plan. To maintain eligibility in the program, the following are required: (1) a prior authorization request has been submitted and/or coverage remains unavailable for the patient; and (2) if the prior authorization is denied by the payer, the prescriber must submit an appeal within the first sixty (60) days of the prior authorization denial and a prior authorization must be submitted every six (6) months thereafter or documentation as may otherwise be required by the payer. UCB reserves the right to rescind, revoke, or amend this Program without notice.

CIMplicity Savings Card Eligibility

Available to individuals with commercial prescription insurance coverage for a valid prescription of an FDA-approved indication for CIMZIA. Not valid for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal- or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (ie, Medicare, Medicaid, Medigap, TRICARE, VA, and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice.

The CIMplicity program is provided as a service of UCB and is intended to support the appropriate use of CIMZIA. The CIMplicity program may be amended or canceled at any time without notice. Eligibility and restrictions apply.

LMN: letter of medical necessity; PA: prior authorization; PAP: Patient Assistance Program.

IMPORTANT SAFETY INFORMATION & INDICATIONS

IMPORTANT SAFETY INFORMATION

Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

INDICATIONS

CIMZIA is indicated for:

  • Reducing signs and symptoms of Crohn’s disease (CD) and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy
  • Treatment of adults with moderately to severely active rheumatoid arthritis (RA)
  • Treatment of adult patients with active psoriatic arthritis (PsA)
  • Treatment of adults with active ankylosing spondylitis (AS)
  • Treatment of adults with moderate-to-severe plaque psoriasis (PSO) who are candidates for systemic therapy or phototherapy
  • Treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation

IMPORTANT SAFETY INFORMATION (CONT)

CONTRAINDICATIONS

CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria.

SERIOUS INFECTIONS

Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue CIMZIA if a patient develops a serious infection or sepsis.

Reported infections include:

  • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before CIMZIA use and during therapy. Initiate treatment for latent TB prior to CIMZIA use.
  • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
  • Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with CIMZIA prior to initiating therapy in the following patients: with chronic or recurrent infection; who have been exposed to TB; with a history of opportunistic infection; who resided in or traveled in regions where mycoses are endemic; with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

  • Do not start CIMZIA during an active infection, including localized infections.
  • Patients older than 65 years, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants may be at greater risk of infection.
  • If an infection develops, monitor carefully and initiate appropriate therapy.

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

  • Consider the risks and benefits of CIMZIA treatment prior to initiating or continuing therapy in a patient with known malignancy.
  • In clinical trials, more cases of malignancies were observed among CIMZIA-treated patients compared to control patients.
  • In CIMZIA clinical trials, there was an approximately 2-fold higher rate of lymphoma than expected in the general U.S. population. Patients with rheumatoid arthritis, particularly those with highly active disease, are at a higher risk of lymphoma than the general population.
  • Malignancies, some fatal, have been reported among children, adolescents, and young adults being treated with TNF blockers. Approximately half of the cases were lymphoma, while the rest were other types of malignancies, including rare types associated with immunosuppression and malignancies not usually seen in this patient population.
  • Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including CIMZIA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis, and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treating with CIMZIA in these patient types.
  • Cases of acute and chronic leukemia were reported with TNF blocker use.

HEART FAILURE

  • Worsening and new onset congestive heart failure (CHF) have been reported with TNF blockers. Exercise caution and monitor carefully.

HYPERSENSITIVITY

  • Angioedema, anaphylaxis, dyspnea, hypotension, rash, serum sickness, and urticaria have been reported following CIMZIA administration. If a serious allergic reaction occurs, stop CIMZIA and institute appropriate therapy. The needle shield inside the removable cap of the CIMZIA prefilled syringe contains a derivative of natural rubber latex which may cause an allergic reaction in individuals sensitive to latex.

HEPATITIS B VIRUS REACTIVATION

  • Use of TNF blockers, including CIMZIA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases have been fatal.
  • Test patients for HBV infection before initiating treatment with CIMZIA.
  • Exercise caution in patients who are carriers of HBV and monitor them before and during CIMZIA treatment.
  • Discontinue CIMZIA and begin antiviral therapy in patients who develop HBV reactivation. Exercise caution when resuming CIMZIA after HBV treatment.

NEUROLOGIC REACTIONS

  • TNF blockers, including CIMZIA, have been associated with rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, including multiple sclerosis, seizure disorder, optic neuritis, peripheral neuropathy, and Guillain-Barré syndrome.

HEMATOLOGIC REACTIONS

  • Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with CIMZIA.
  • Consider stopping CIMZIA if significant hematologic abnormalities occur.

DRUG INTERACTIONS

  • Do not use CIMZIA in combination with other biological DMARDs.

AUTOIMMUNITY

  • Treatment with CIMZIA may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

IMMUNIZATIONS

  • Patients on CIMZIA should not receive live or live-attenuated vaccines.

ADVERSE REACTIONS

  • The most common adverse reactions in CIMZIA clinical trials (≥8%) were upper respiratory infections (18%), rash (9%), and urinary tract infections (8%).

Please refer to full Prescribing Information.